Johnson & Johnson (NYSE:JNJ) is Hyman Charles D’s 9th Largest Position

Hyman Charles D trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 303,032 shares of the company’s stock after selling 1,502 shares during the period. Johnson & Johnson comprises 2.6% of Hyman Charles D’s investment portfolio, making the stock its 9th biggest holding. Hyman Charles D’s holdings in Johnson & Johnson were worth $47,937,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Christopher J. Hasenberg Inc purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $31,000. Keener Financial Planning LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $40,000. WFA Asset Management Corp increased its stake in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $45,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, July 1st. Bank of America dropped their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Finally, Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Up 0.4 %

NYSE JNJ opened at $150.52 on Monday. The stock has a market cap of $362.25 billion, a PE ratio of 9.38, a P/E/G ratio of 2.52 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The business has a 50 day moving average price of $147.94 and a two-hundred day moving average price of $153.46. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.30%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.